<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36008">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637804</url>
  </required_header>
  <id_info>
    <org_study_id>JP-MKTG-201512</org_study_id>
    <nct_id>NCT02637804</nct_id>
  </id_info>
  <brief_title>Daily Disposable Silicone Hydrogel Contact Lens, Stenfilcon A, Clinical Study</brief_title>
  <official_title>Daily Disposable Silicone Hydrogel Contact Lens, Stenfilcon A, Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coopervision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coopervision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical evaluation of stenfilcon A compared with narafilcon A and delefilcon A

      This is a total 120 subject, randomized, open label, bilateral wear, two week crossover
      study (each lens for 1 week) evaluating the clinical performance of stenfilcon A spherical
      lenses compared to narafilcon A or delefilcon A spherical lenses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the clinical performance of stenfilcon A compared with
      narafilcon A and delefilcon A.

      The study group will be allocated into two groups, of 60 subjects each, based on the control
      lenses, narafilcon A and delefilcon A spherical lenses.

      Study groups:

        1. stenfilcon A vs. narafilcon A group

        2. stenfilcon A vs. delefilcon A group
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain and foreign body sensation (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Subjective ratings of pain and foreign body sensation for stenfilcon A and narafilcon A assessed at baseline. 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain and foreign body sensation (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Subjective ratings of pain and foreign body sensation for stenfilcon A and narafilcon A assessed at 1 week. 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Itching sensation on insertion (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Subjective ratings of itching sensation on insertion for stenfilcon A and narafilcon A assessed at baseline. 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Itching sensation on removal (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Subjective ratings of itching sensation on insertion for stenfilcon A and narafilcon A assessed at 1 week. 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Red eye (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Subjective ratings of red eye for stenfilcon A and narafilcon A assessed at baseline. 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Red eye (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Subjective ratings of red eye for stenfilcon A and narafilcon A assessed at 1 week. 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dryness (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Subjective ratings of dryness for stenfilcon A and narafilcon A assessed at baseline. (Scale 0-10, 0=extremely dried and cannot wear lens, 10=not dried at all).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dryness (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Subjective ratings of dryness for stenfilcon A and narafilcon A assessed at 1 week. (Scale 0-10, 0=extremely dried and cannot wear lens, 10=not dried at all).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comfort (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Subjective ratings of comfort for stenfilcon A and narafilcon A assessed at baseline. (Scale 0-10, 0=extremely uncomfortable cannot wear at all, 10=very comfortable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comfort (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Subjective ratings of comfort for stenfilcon A and narafilcon A assessed at 1 week. (Scale 0-10, 0=extremely uncomfortable cannot wear at all, 10=very comfortable).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vision (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Subjective ratings of vision for stenfilcon A and narafilcon A assessed at baseline. (Scale 0-10, 0=cannot see at all, 10=very clear).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vision (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Subjective ratings of vision for stenfilcon A and narafilcon A assessed at 1 week. (Scale 0-10, 0=cannot see at all, 10=very clear).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Handling (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Subjective ratings of handling for stenfilcon A and narafilcon A assessed at baseline. (Scale 0-10, 0=not good at all, 10=no problem at all).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Handling (subjective rating) - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Subjective ratings of handling for stenfilcon A and narafilcon A assessed at 1 week. (Scale 0-10, 0=not good at all, 10=no problem at all).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall wearing satisfaction - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Subjective ratings of overall wearing satisfaction for stenfilcon A and narafilcon A assessed at baseline. (Scale 0-10, 0=extremely unsatisfied, 10=very satisfied).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall wearing satisfaction - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Subjective ratings of overall wearing satisfaction for stenfilcon A and narafilcon A assessed at 1 week. (Scale 0-10, 0=extremely unsatisfied, 10=very satisfied).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lens preference - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Subjective ratings of lens preference for stenfilcon A and narafilcon A assessed at 1 week. (5 possible ratings: Definitely stenfilcon A, Somewhat stenfilcon A, No difference, Somewhat habitual lens, Definitely habitual lens).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lens fit - horizontal centration - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Lens fit evaluation of horizontal centration for stenfilcon A and narafilcon A assessed at baseline. (Temporal, Little temporal, Centered, Little nasal, Nasal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lens fit - horizontal centration - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Lens fit evaluation of horizontal centration for stenfilcon A and narafilcon A assessed at 1 week. (Temporal, Little temporal, Centered, Little nasal, Nasal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lens fit - vertical centration - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Lens fit evaluation of vertical centration for stenfilcon A and narafilcon A is assessed at baseline. (Up, Little up, Centered, Little low, Low)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lens fit - vertical centration - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Lens fit evaluation of vertical centration for stenfilcon A and narafilcon A is assessed at 1 week. (Up, Little up, Centered, Little low, Low)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lens fit - post-blink movement - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Lens fit evaluation of post-blink movement for stenfilcon A and narafilcon A is assessed at baseline. (Tight, Little tight, Optimal, Little loose, Loose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lens fit - post-blink movement - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Lens fit evaluation of post-blink movement for stenfilcon A and narafilcon A is assessed at 1 week. (Tight, Little tight, Optimal, Little loose, Loose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lens fit - tightness on up gaze blink lag - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Lens fit evaluation of tightness on up gaze blink lag for stenfilcon A and narafilcon A is assessed at baseline (insertion). (Optimal, Acceptable, No lag, Falls from cornea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lens fit - tightness on up gaze blink lag - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Lens fit evaluation of tightness on up gaze blink lag for stenfilcon A and narafilcon A is assessed at 1 week. (Optimal, Acceptable, No lag, Falls from cornea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lens fit overall - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Lens fit evaluation overall for stenfilcon A and narafilcon A is assessed at baseline. (Optimal, Almost optimal, Border line to wear, Not acceptable (cannot wear)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lens fit overall - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Lens fit evaluation overall for stenfilcon A and narafilcon A is assessed at 1 week. (Optimal, Almost optimal, Border line to wear, Not acceptable (cannot wear)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival redness - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Conjunctival redness for stenfilcon A and naralfilcon A is assessed at baseline. (Scale 0-4, 0.5 steps 0= 4=) N - nasal, T - temporal, S - superior, I - interior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival redness - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Conjunctival redness for stenfilcon A and naralfilcon A is assessed at 1 week. (Scale 0-4, 0.5 steps 0= 4=)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limbal redness - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Limbal redness for stenfilcon A and narafilcon A assessed at baseline. (Scale 0-4, 0.5 steps 0= 4=) N - nasal, T - temporal, S - superior, I - interior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Limbal redness - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Limbal redness for stenfilcon A and narafilcon A assessed at 1 week. (Scale 0-4, 0.5 steps 0= 4=) N - nasal, T - temporal, S - superior, I - interior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal staining - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Corneal staining for stenfilcon A and narafilcon A is assessed at baseline. (Scale 0-4, 0.5 steps 0= 4=) C - central, N - nasal, T - temporal, S - superior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal staining - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Corneal staining for stenfilcon A and narafilcon A is assessed at 1 week. (Scale 0-4, 0.5 steps 0= 4=) C - central, N - nasal, T - temporal, S - superior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal neovascularization - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Corneal neovascularization for stenfilcon A and narafilcon A is assessed at baseline. (Scale 0-4, 0.5 steps 0= 4=)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal neovascularization - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Corneal neovascularization for stenfilcon A and narafilcon A is assessed at 1 week. (Scale 0-4, 0.5 steps 0= 4=)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival staining - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Conjunctival staining for stenfilcon A and naralfilcon A is assessed at baseline. (Scale 0-4, 0.5 steps 0= 4=) N - nasal, T - temporal, S - superior, I - interior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival staining - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Conjunctival staining for stenfilcon A and naralfilcon A is assessed at 1 week. (Scale 0-4, 0.5 steps 0= 4=) N - nasal, T - temporal, S - superior, I - interior</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal oedema - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Corneal oedema for stenfilcon A and naralfilcon A is assessed at baseline. (Scale 0-4, 0.5 steps 0= 4=)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal oedema - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Corneal oedema for stenfilcon A and naralfilcon A is assessed at 1 week. (Scale 0-4, 0.5 steps 0= 4=)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Papillary conjunctivitis - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>Baseline</time_frame>
    <description>Papillary conjunctivitis for stenfilcon A and naralfilcon A is assessed at baseline. (Scale 0-4, 0.5 steps 0= 4=)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Papillary conjunctivitis - stenfilcon A/narafilcon A and stenfilcon A/delefilcon A</measure>
    <time_frame>1 week</time_frame>
    <description>Papillary conjunctivitis for stenfilcon A and naralfilcon A is assessed at 1 week. (Scale 0-4, 0.5 steps 0= 4=)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>stenfilcon A (narafilcon A group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized and crossover to wear either the stenfilcon A pair of lenses or narafilcon A pair of lenses in one week of daily disposable wear for each pair of lenses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>narafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized and crossover to wear either the stenfilcon A pair of lenses or narafilcon A pair of lenses in one week of daily disposable wear for each pair of lenses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stenfilcon A (delefilcon A group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized and crossover to wear either the stenfilcon A pair of lenses or delefilcon A pair of lenses in one week of daily disposable wear for each pair of lenses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>delefilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be randomized and crossover to wear either the stenfilcon A pair of lenses or delefilcon A pair of lenses in one week of daily disposable wear for each pair of lenses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>stenfilcon A pair of lenses</intervention_name>
    <description>stenfilcon A contact lens</description>
    <arm_group_label>stenfilcon A (narafilcon A group)</arm_group_label>
    <arm_group_label>stenfilcon A (delefilcon A group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>narafilcon A pair of lenses</intervention_name>
    <description>narafilcon A contact lens</description>
    <arm_group_label>narafilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>delefilcon A pair of lenses</intervention_name>
    <description>delefilcon A contact lens</description>
    <arm_group_label>delefilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - A person is eligible for inclusion in the study if he/she:

          -  Is over 18 years of age (inclusive)

          -  Has had a self-reported visual exam in the last two years

          -  Is an adapted daily disposable non-silicone hydrogel spherical contact lens wearer

          -  Can achieve best corrected spectacle distance visual acuity of 20/25 or better in
             each eye.

          -  Can achieve a distance visual acuity of 20/30 or better in each eye with the study
             contact lenses.

          -  Has clear corneas and no active ocular disease

          -  Has read, understood and signed the information consent letter.

          -  Has a CL (Contact Lens) spherical prescription between - 0.75 and - 8.00 (inclusive)

          -  Is willing to comply with the wear schedule.

          -  Is willing to comply with the visit schedule

        Exclusion Criteria:

        - A person will be excluded from the study if he/she:

          -  Is not a habitual wearer of daily disposable non-silicone hydrogel spherical contact
             lenses

          -  Has a CL prescription outside the range of the inclusion power range

          -  Has a spectacle cylinder â‰¥1.00D of cylinder in either eye.

          -  Has a history of not achieving comfortable CL wear (5 days per week; &gt; 8 hours/day)

          -  Has contact lens best corrected distance vision worse than 20/25 in either eye

          -  Presence of clinically significant (grade 2-4) anterior segment abnormalities

          -  Presence of ocular or systemic disease or need of medications which might interfere
             with contact lens wear

          -  Slit lamp findings that would contraindicate contact lens wear

          -  Has a known history of corneal hypoesthesia (reduced corneal sensitivity)

          -  Has aphakia, keratoconus or a highly irregular cornea.

          -  Has undergone corneal refractive surgery.

          -  Is participating in any other type of eye related clinical or research study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuji Kodama, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Kodama Eye Clinic</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 6, 2016</lastchanged_date>
  <firstreceived_date>December 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
